Vera Therapeutics Future Growth
Future criteria checks 0/6
Vera Therapeutics is forecast to grow earnings and revenue by 26.5% and 71.9% per annum respectively. EPS is expected to grow by 29.5% per annum. Return on equity is forecast to be -49.2% in 3 years.
Key information
26.5%
Earnings growth rate
29.5%
EPS growth rate
Biotechs earnings growth | 24.5% |
Revenue growth rate | 71.9% |
Future return on equity | -49.2% |
Analyst coverage | Good |
Last updated | 10 Apr 2024 |
Recent future growth updates
Recent updates
Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect
Jan 25Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove
Sep 06Vera Therapeutics GAAP EPS of -$0.55 beats by $0.17
Aug 10Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth
Feb 16Vera: Biotech With 3 Mid-Stage Programs With Potential For Success
Jan 19Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot
Jan 07We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth
Oct 25Vera Therapeutics soars 16% on three new favorable view from analysts
Jun 08Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 39 | -149 | -117 | -195 | 8 |
12/31/2025 | N/A | -130 | -121 | -146 | 8 |
12/31/2024 | N/A | -118 | -106 | -119 | 8 |
12/31/2023 | N/A | -96 | -92 | -92 | N/A |
9/30/2023 | N/A | -103 | -88 | -88 | N/A |
6/30/2023 | N/A | -107 | -84 | -84 | N/A |
3/31/2023 | N/A | -102 | -85 | -85 | N/A |
12/31/2022 | N/A | -89 | -68 | -68 | N/A |
9/30/2022 | N/A | -73 | -58 | -53 | N/A |
6/30/2022 | N/A | -56 | -45 | -40 | N/A |
3/31/2022 | N/A | -45 | -34 | -29 | N/A |
12/31/2021 | N/A | -33 | -29 | -24 | N/A |
9/30/2021 | N/A | -59 | -45 | -45 | N/A |
6/30/2021 | N/A | -55 | -42 | -42 | N/A |
3/31/2021 | N/A | -56 | -37 | -37 | N/A |
12/31/2020 | N/A | -53 | -35 | -35 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VERA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VERA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VERA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VERA is forecast to have no revenue next year.
High Growth Revenue: VERA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VERA is forecast to be unprofitable in 3 years.